Endogenous pyrogen (EP), a small protein released from polymorphonuclear (PMN) and mononuclear cells after appropriate stimulation, has been implicated in the pathogenesis of fever in a number of experimental models (2) . Previous studies have defined some of the characteristics of the early process of pyrogen production and release by human blood leukocytes, predominantly PMN, after activation in vitro by a stimulus such as phagocytosis (6, 24) . These data support the concept that cell activation leads initially to synthesis of one or more important proteins, including a postulated enzyme which converts a "pro-pyrogen" in the cell to a pyrogenically active molecule. Once activated, leukocytes release pyrogen for many hours (5, 6, 26) .
The characteristics of the later stages of pyrogen production and release by blood leukocytes are poorly understood. It has been postulated that EP, or other substances, released from activated cells might induce activation and initiate pyrogen production by neighboring cells (3, 27) . Conversely, products of activated cells might modify the amount of released pyrogen by accelerating its degradation or by inhibiting further pyrogen production by some kind of feedback inhibition. Evidence supporting this latter mechanism has been reported (26) .
The following studies were designed to exam-451 ine a possible role of cell products, including EP, in induction, augmentation, or suppression of pyrogen release by blood leukocytes.
MATERIALS AND METHODS
Preparation and incubation of leukocytes. Methods for preparation and incubation of leukocytes were as described previously (6) . All materials, glassware, and reagents used in this and subsequent procedures were sterile and pyrogen free. Briefly, heparinized blood from normal donors was mixed with 3% dextran, and the leukocytes were recovered from the supernatant by centrifugation. The remaining red cells were removed by hypotonic lysis. Incubations were usually carried out in modified KrebsRinger phosphate buffer (pH 7.4) containing 15% homologous serum, 10 U of heparin per ml, 150 mg% of glucose, and 600 U of penicillin per ml or 50 U of penicillin per ml plus 50 mg of streptomycin. Leukocyte concentrations were usually 107/ml. For preparation of EP-containing supematants, autoclaved Staphylococcus albus, prepared as described previously (6), was added to flasks as a phagocytic stimulus. After 2 h of incubation, the flask contents were centrifuged at 600 x g for 15 min, and the cells were resuspended in Krebs-Ringer phosphate buffer with glucose and penicillin but no serum. Flasks were then incubated overnight in a stationary incubator at 37 C. Supernatants were recovered by centrifugation at 2,000 *x g for 30 min, cultured to confirm sterility, and stored at 4 C for 1 to 7 days before assay. Pyrogen content of such supernatants is not significantly INFECT. IMMUNrry altered by storage at 4 C for 1 week (unpublished data).
Pyrogen assay. Rabbits were injected intravenously, and temperatures were measured either at 15-min intervals by means of a Tele-Thermometer (Yellow Springs Instrument Co., Inc.) or monitored continuously with a Rustrak automatic recorder (Timer Service Co., Inc., Norwood, Mass.). In all but a few instances, all samples in each experiment were injected into the same group of rabbits. In most experiments, supernatants from 3 x 107 to 5 x 107 leukocytes were chosen as a dose for each rabbit. When careful quantification of pyrogen content was necessary, various doses of a supernatant were injected into each rabbit until a twofold change in concentration of the test solution produced approximately a twofold increase or decrease in maximal height of fever (AT) in that animal. The pyrogen content was then calculated per number of leukocytes, based on this linear dose-response relationship, and expressed as derived maximal height of fever (derived AT). Data supporting the validity of this method is presented in Results.
Preparation of partially purified EP. The procedure was similar to that described previously (6) . EP-containing supernatant, prepared as described above, was filtered through a Sephadex G-75 column equilibrated with saline buffered with 0.05 M KH2PO4, pH 6.5. The fractions eluting between approximately 10,000 and 30,000 daltons were collected, pooled, cultured, and assayed for pyrogen content.
Reagents. Actinomycin D was prepared as described previously (6) . Between 0.05 and 0.1 ml was placed in an incubation flask, such that the final flask content equaled 5 ,g of actinomycin D per ml of cell suspension. In some experiments, pH was altered by addition of 0.1 N HCl; before injection, pH of supernatants was returned to 7.2 to 7.6 by addition of 0.1 N NaOH and a small volume of Krebs-Ringer phosphate buffer, pH 7.4 . Broken cells were prepared by five cycles of freeze-thawing in a dry ice-acetone bath.
RESULTS
Assay of human leukocyte pyrogen in rabbits. In two previous studies (11, 26) linear relationship existed between pyrogen content and average height of fever. Although the responses to any particular dose varied widely among individual rabbits, each animal responded to a doubling of some low pyrogen dose with a 1.5-to 2-fold increase in AT. Therefore, in experiments such as those below where only small amounts of pyrogen and relatively few rabbits are available for assays, a modification of the assay proposed by Murphy et al. (23) Effect of cell products on preformed EP. Experiments were first done to determine whether the pyrogenicity of a solution containing endogenous pyrogen is altered by incubation with activated cells or their products. Actinomycintreated cells were used for this purpose, since previous studies have shown that, in the presence of actinomycin D, leukocytes exhibit normal phagocytosis, increases in oxygen consumption, and granule lysis (9) , but fail to produce pyrogen (6) . The experiments were designed as follows. Pyrogen-containing supernatant (referred to below as EP-supernatant) was obtained from leukocytes stimulated by phagocytosis, and pyrogen content was assayed. Fresh leukocytes were then obtained from the same donor, incubated for 1 to 2 h with actinomycin and heat-killed staphylococci, and then suspended in fresh medium containing pyrogenic EP-supernatant. Flasks with normal and actinomycin-treated leukocytes plus bacteria were also incubated to provide positive and negative controls. In addition, two flasks contained EP-supernatant without cells; one was placed at 4 C, and the other was placed at 37 C. After overnight incubations, all supernatants were assayed for pyrogen content (Table 1, middle row). When compared with the pyrogenic activity of the refrigerated sample, EP-supernatant incubated at 37 C lost only about one-fifth of its pyrogenicity. These results are similar to those reported for the heat stability of rabbit leukocyte pyrogen (18) . In the presence of stimulated, actinomycin-treated cells, pyrogenicity did not decrease. Similar results were obtained when the initial superna- In other experiments (Table 1 , bottom row), identical studies were carried out with incubation media adjusted to pH 5.0 at the time the EP-supernatant was added. In other studies (not shown), normal, stimulated leukocytes which had been disrupted by freeze-thawing were used in place of actinomycin-treated cells. Significant loss of pyrogenicity from the EPsupernatant occurred in all instances during incubation at 37 C at pH 5.0. It should be noted that the EP-supernatant itself contained products of activated cells, since it was produced from cells stimulated by phagocytosis. These results indicate that, at pH 5.0 in the presence of activated cells or cell products, pyrogenicity of EP is markedly reduced.
Influence of cell products on EP production by activated cells. In a previous report (26) , enhanced pyrogen production was reported to occur when stimulated leukocytes were incubated in a dilute suspension or when the medium was changed once during incubation. Preliminary results from this laboratory, before quantitative assay techniques were used, supported this finding (1). It was hypothesized that some cell product might influence pyrogen release by a process of feedback inhibition. The following studies were done to look for such a mechanism.
In the first group of experiments (Table 2) , In the final series of experiments (Table 4) , a preparation of partially purified EP was obtained (see Materials and Methods), and portions were incubated with normal leukocytes. Control flasks included those with the EP preparation without leukocytes, and leukocytes incubated with staphylococci, to demonstrate their pyrogen-producing capacity. No additional pyrogen appeared in the supernatants of flasks containing leukocytes and EP during an 18-h incubation, even though these leukocytes were capable of pyrogen production. These results, then, do not support the concept that EP, released from stimulated leukocytes, acts to induce pyrogen production by normal leukocytes. DISCUSSION There is now considerable evidence that endogenous pyrogen, a small protein produced and released from stimulated leukocytes, is responsible for fever both in experimental animal models and in febrile diseases of man. The types of stimuli which activate cells to release pyrogen include many that also elicit inflammatory responses in vivo; these include endotoxins from gram-negative bacteria, phagocytosis, antigen-antibody reactions, delayed hypersensitivity responses, and, for human cells, pyrogenic steroids (2).
Although both PMN and mononuclear leukocytes can produce pyrogen, detailed studies concerning the mechanism of pyrogen production and release have been made only of mixed blood or acute peritoneal exudate leukocytes, both predominantly PMN in type. In this discussion, leukocyte pyrogen, or EP, refers to material obtained from such cells. The following sequence has been established (6, 24) . (i) Normal, unstimulated cells contain little or no pyrogen. (ii) After stimulation, as for example by phagocytosis, an initial 1-to 2-h activation stage is needed before significant pyrogen, either within or without the cell, is detectable. During this time, new ribonucleic acid and protein synthesis must occur. (iii) Once pyrogen production and release begins, it continues for hours. Addition of inhibitors of protein synthesis or metabolism, such as puromycin or NaF, has no effect at this stage, but production and release ceases if the cells are placed at 4 C or disrupted.
When an inflammatory stimulus acts in vivo, it is likely that only a few cells are activated initially. Under such conditions, products released from a small number of activated leukocytes might in turn stimulate EP production in others, thus magnifying the fever-inducing effect of the original inflammatory stimulus. Such a mechanism has been postulated to explain the second, larger peak of fever that follows injection of large doses of EP-containing supernatant into rabbits (3) . During this second fever, the level of circulating EP exceeds that found during the initial fever, suggesting that EP is being produced in vivo. Some evidence implicating blood leukocytes in this process has been reported (27) . In analogous systems, factors present in PMN leukocytes have been shown to have augmenting effects on various other aspects of the inflammatory response. Such substances include chemotactic factors for both PMN (22) and mononuclear cells (28) , kininogenases (14) , and basic proteins which increase vascular permeability (25). In the studies reported here, as well as in those previously described (6) , no stimulatory factor for pyrogen production was identified. Of particular interest, a preparation of partially purified EP did not initiate pyrogen production by blood leukocytes. Thus, no evidence was found for an auto-activation mechanism in the generation of pyrogen from human PMN leukocytes after initial application of an inflammatory stimulus.
Recent evidence indicates that certain mononuclear cells, such as phagocytes of the reticuloendothelial system, play an important role in many experimental fevers (12, 16) . Human monocyte pyrogen has recently been characterized and shown to be distinct from PMN leukocyte pyrogen (13) . Monocyte pyrogen (molecular weight, 38,000) would have been excluded from the Sephadex fractions making up the partially purified EP used in these studies; however, for some reason, large-molecularweight pyrogen is not present in preparations of pyrogen from mixed leukocytes of human buffy coat (13) . Thus, blood leukocyte pyrogen obtained in vitro probably derives almost entirely from PMN leukocytes. In vivo, mononuclear cells, rather than PMN leukocytes, may be responsible for the prolonged fevers that accompany certain inflammatory states. Further studies are needed to examine how interactions between inflammatory stimuli, PMN leukocytes, and mononuclear cells affect the induction and persistence of fever.
There is no information about control mechanisms that might limit production of EP by stimulated blood leukocytes. In one study, the amount of EP released per cell was apparently increased as the concentration of cells in suspension was decreased (26) . This observation suggested that some form of feedback inhibition might operate to regulate the amount of EP generated at an inflammatory focus. Since most acute fevers are of short duration, such a hypothesis is attractive. However, in the studies described here, leukocyte production of pyrogen continued normally even when s'ubstantial amounts of pyrogen and other products of stimulated cells were present in the medium. Contrary to previous interpretations (1, 6), careful assays indicate that production of EP from stimulated blood leukocytes in vitro continues at a fairly constant rate for 10 to 16 h once it begins (Table 2 and unpublished data). When the volume of incubation medium was increased fivefold, only a small change was observed in the amount of total pyrogen produced per cell. Actinomycin, puromycin, or NaF also failed to suppress pyrogen release by cells when added either 2 h after activation (6, 24) or at a 6-h time interval (unpublished data). Thus, it is likely that PMN leukocytes, once activated, produce pyrogen continuously until they die or are destroyed. Since this process has been suppressed only by iodoacetate, among the agents tested, presumably there is some simple enzymatic conversion of a precursor molecule to an active pyrogen at this final stage.
The fate of pyrogen after its release from cells in vivo is unknown. Although circulating EP can be easily demonstrated in febrile rabbits (4), only once has a small amount of EP apparently been detected in man (15) . One study in rabbits suggested that circulating EP has a rapid half-life of about 40 min (21) . However, this is a questionable finding, since it is based on the rate of the animal's defervescence after injection of a large dose of EP. This response is a complicated one, involving the whole thermoregulatory system, and cannot be assumed to reflect directly the amount of circulating EP. Studies on the stability of crude leukocyte pyrogen in vitro have shown that pyrogenicity is retained under normal conditions of incubation. For example, leukocyte pyrogen from rabbit exudate cells retains its pyrogenicity during overnight incubation in saline at 37 C (18) . More purified preparations rapidly lose activity even in the cold (23) , perhaps through activation of associated proteolytic enzymes during the initial purification procedures. Rabbit (19), but not human (8) , EP is inactivated at alkaline pH in the absence of reducing agents.
The studies reported here indicate that crude human leukocyte EP preparations, containing other products of activated cells, when incubated overnight in serum buffer at pH 7.4, retain most of their pyrogenicity. However, when the pH is lowered to 5.0, there is marked inactivation of pyrogen. Many hydrolytic enzymes are released from stimulated leukocytes as degranulation occurs (17); several proteases, including cathepsins, have acid pH optima (10) . EP is inactivated by trypsin and Pronase (7) . Thus, it is likely that the observed loss of pyrogenicity at acid pH in the in vitro system is due to the action of proteolytic enzymes released from the phagocytizing cells. However, since a purified preparation of EP was not available for these experiments, it was not possible to test the effect of incubation at acid pH on the pyrogenic molecule itself. Inactivation of pyrogen at local sites of inflammation, where the pH is frequently acid (20) , could be an important mechanism that regulates entry of EP into the blood and thus modifies fever.
